Plavix is a brand name of clopidogrel, approved by the FDA in the following formulation(s):
PLAVIX (clopidogrel bisulfate - tablet; oral)
Manufacturer: SANOFI AVENTIS US
Approval date: November 17, 1997
Strength(s): EQ 75MG BASE
Manufacturer: SANOFI AVENTIS US
Approval date: September 20, 2007
Strength(s): EQ 300MG BASE [RLD]
Has a generic version of Plavix been approved?
No. There is currently no therapeutically equivalent version of Plavix available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plavix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
Patent 4,847,265
Issued: July 11, 1989
Inventor(s): Badorc; Alain & Frehel; Daniel
Assignee(s): Sanofi
The present invention relates to the dextro-rotatory enantiomer of Formula ##STR1## and its pharmaceutically acceptable salts with platelet aggregation inhibiting activity. The invention also relates to a process for the preparation of this compound starting from the racemate and the pharmaceutical compositions containing it.Patent expiration dates:
- November 17, 2011✓✓
- May 17, 2012✓
- November 17, 2011
Method for the secondary prevention of ischemic events
Patent 5,576,328
Issued: November 19, 1996
Inventor(s): Herbert; Jean-Marc & Frehel; Daniel & Bernat; Andr e & Badorc; Alain & Savi; Pierre & Delebass ee; Denis & Kieffer; Gilles & Defreyn; Ghislain & Maffrand; Jean-Pierre
Assignee(s): Elf Sanofi
The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.Patent expiration dates:
- January 31, 2014✓✓
- July 31, 2014✓
- January 31, 2014
Polymorphic clopidogrel hydrogenesulphate form
Patent 6,429,210
Issued: August 6, 2002
Inventor(s): André ; Bousquet & Bertrand; Castro & Jean; Saint-Germain
Assignee(s): Sanofi-Synthelabo
Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparation.Patent expiration dates:
- June 10, 2019✓✓
- December 10, 2019✓
- June 10, 2019
Polymorphic form of clopidogrel hydrogen sulphate
Patent 6,504,030
Issued: January 7, 2003
Inventor(s): André ; Bousquet & Bertrand; Castro & Jean; Saint-Germain
Assignee(s): Sanofi-Synthelabo
Novel orthorombic polymorph of clopidogrel hydrogen sulfate or hydrogen sulfate of methyl (+)-(S)-&agr;-(2-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-acetate and a process for its preparationPatent expiration dates:
- June 10, 2019✓
- December 10, 2019✓
- June 10, 2019
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- May 6, 2014 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- November 6, 2014 - PEDIATRIC EXCLUSIVITY
See also...
- Plavix Consumer Information (Drugs.com)
- Plavix Consumer Information (Wolters Kluwer)
- Plavix Consumer Information (Cerner Multum)
- Plavix Advanced Consumer Information (Micromedex)
- Plavix AHFS DI Monographs (ASHP)
- Clopidogrel Consumer Information (Wolters Kluwer)
- Clopidogrel Consumer Information (Cerner Multum)
- Clopidogrel Advanced Consumer Information (Micromedex)
- Clopidogrel Bisulfate AHFS DI Monographs (ASHP)
No comments:
Post a Comment